Print（PDF/105KB） Jul. 25, 2017 Corporate

Sumitomo Dainippon Pharma Announces Investment in DEFTA Healthcare Technologies, L.P.

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) announced today that it has entered into an agreement to invest in DEFTA Healthcare Technologies, L.P. (hereinafter referred to as "D.H.C.T."), an investment partnership established by DEFTA Partners (Principal Office: California, U.S.; CEO: George Hara), assenting to its basic policies. Under this agreement, Sumitomo Dainippon Pharma will make investments up to a cumulative total of US$10 million (approximately JPY1.1 billion) in D.H.C.T.

D.H.C.T. seeks investment opportunities in venture firms operating in the U.S., Israel, and Japan in such promising fields as leading-edge medical treatments and regenerative medicine, next-generation medical devices, and healthcare IoT (Internet of Things) and ICT (Information and Communication Technology), with the intention of creating new industries.

Sumitomo Dainippon Pharma hopes that its investments in D.H.C.T. will allow it not only to acquire information on the most up-to-date technologies in regenerative medicine, cell therapy, leading-edge medical treatments, and healthcare IoT/ICT, but also to gain efficient access to information on venture firms in those fields, which may then lead to even more partnerships.

(Reference: D.H.C.T. Outline)

Name :	DEFTA Healthcare Technologies, L.P.
Basic principles :	Create new industries by investing in companies that develop innovative technologies vital to humanity. Industrialize innovative medical science to enable people to enjoy a long and healthy lifespan.
Offices :	California, U.S.; Japan
Investment size :	Up to US$100 million
Term :	10 years (planned)
Investment fields :	Leading-edge medical treatments and regenerative medicine, next-generation medical devices, and healthcare IoT/ICT
Geographical Target :	U.S., Israel, and Japan
Website :	http://deftapartners.com/ （DEFTA Partners）